A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)

NCT03435601 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Anifrolumab
DRUG: Placebos

Sponsor

Josef Smolen, Univ. Prof. Dr.